🇺🇸 FDA
Pipeline program

LY3471851

17238

Phase 2 small_molecule completed

Quick answer

LY3471851 for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 2 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Systemic Lupus Erythematosus
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials